synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
In 1993, True came in contact with the Tarahumara or Rarámuri runners from Chihuahua, Mexico. In 1994, he began spending his winters running in the Copper Canyons, where he built a hut and began establishing a relationship with the Tarahumara natives.
Under Bello's direction, SoBe launched a line of "3C" Elixirs (containing calcium, carnitine and chromium) in varieties such as Orange-Carrot, Orange-Tomato (including lycopene), Energy (with guarana, yohimbe and arginine), Power (taurine, creatine and proline), Zen Blend (triple ginseng tea with schizandra), Wisdom (with ginkgo biloba, St. John's wort and gotu kola) and Eros (with dong quai, damiana, foti and zink). Other fun SoBe products included Lizzard Blizzard, Tsunami, Fierce, Courage and Long John Lizard’s Grape Grog. He created the "dueling lizards" design and took a lead role in the company's guerrilla marketing effort, proclaiming himself as the "Lizard King" in radio advertisements. He gave the brand an "attitude" by enlisting athletes who were somewhat out of the mainstream—such as golfer John Daly and downhill skier Bode Miller—as official spokespersons for the brand. The SoBe marketing team also wooed independent beverage distributors, offering them very high margins and a small chunk of equity in the company. From its creation in 1995, SoBe's sales rose rapidly and climbed to $275 million by 2000. The following year, the brand rode the "good-for-you" trend among American consumers to break the quarter billion dollar barrier in 2000. SoBe was sold to PepsiCo for a reported $370 million cash on October 30, 2000. Bello remained with Pepsi overseeing SoBe until early 2004. By the end of 1999 the company had sold 14.8 million cases of drinks and taken in $166.4 million.
== External links == "Mixed Connective Tissue Disease: Causes, Symptoms & Treatment". Cleveland Clinic. 2016-05-26. Nevares, Alana M. (2022-10-06). "Mixed Connective Tissue Disease (MCTD)". Merck Manual Consumer Version.
== External links == Simply stated at mdausa.org[link removed] Creatine+Kinase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) CPK isoenzymes test MedlinePlus Encyclopedia: 003504 CK at Lab Tests Online
Sources: en.wikipedia.org
== Symptoms == The main symptoms of chronic kidney disease in cats are lack of appetite (anorexia), increased drinking (polydipsia), increased urine output (polyuria), fatigue (apathy), vomiting and weight loss. In addition, diarrhea, inflammation of the oral mucosa (stomatitis) with the formation of ulcers (ulcera), increased salivation (hypersalivation) and bad breath may occur as a result of uremia. Increased blood pressure (arterial hypertension) with damage to the eye (fundus hypertonicus, hypertensive retinopathy), anemia (anemia), itching, dehydration, soft tissue calcifications, bleedings and accumulation of water in the tissues (oedemas) are also more frequent accompanying symptoms. In the case of severe uremia, neurological neurology manifestations such as apathy, seizures, delirium, coma, abnormal movements and muscle disorders (myopathies). Typically, the symptoms—in contrast to acute renal failure—occur gradually over weeks, months or even years, and the general condition is poor. In addition, acute kidney failure is initially characterized by reduced urine production. However, an existing mild or moderate chronic kidney disease is often suddenly worsened by an acute event ("exacerbation") and thus becomes conspicuous to the cat owner.
Emerging evidence suggests that the gut microbiome may also provide predictive information for response to immune checkpoint blockade. In a multi-regional study 674 patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade, pre-treatment gut bacterial markers were associated with recurrence, with prediction performing best when patients were compared within groups matched for overall gut microbiome composition, suggesting that microbiome-based biomarkers may be informative but context dependent. PD-1 and PD-L1 inhibitors are closely related to CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors, such as ipilimumab. PD-1 and CTLA-4 are both expressed on activated T cells, but at different phases of immune response. Current clinical trials are evaluating anti-PD-1 and PD-L1 drugs in combination with other immunotherapy drugs blocking LAG3, B7-H3, KIR, OX40, PARP, CD27, and ICOS.
Haüy's theory was generally accepted by his fellow mineralogists in the period 1801–1815 but then came under attack from the German dynamist school led by Christian Samuel Weiss. Weiss and his followers studied the external symmetry of crystals rather than their internal structure. In 1819, Weiss demonstrated the generality of the phenomenon of hemihedry (half of the vertices/edges/faces of a crystal act differently from the other half), thus challenging Haüy's holohedral approach (all vertices/edges/faces of a crystal act in the same manner). Haüy's crystal structure theory was criticised as over-simplistic by William Hyde Wollaston in 1809 and by Henry James Brooke in 1819. Haüy also tended to ignore experimental results that contradicted his structural theory, such as those achieved with the more accurate reflection goniometer invented by Wollaston in 1809. In 1813 Wollaston adopted Dalton's ideas and proposed using sphere packing to model crystal structures. In 1814 André-Marie Ampère published a theory of the chemical combination of substances, based on Haüy's polyhedral forms. However, Ampère's work had little impact on contemporary chemists. In 1819 David Brewster classified crystals according to their optical properties, as isotropic, uniaxial, or biaxial. In a paper published in 1830 Brewster attempted to relate the phenomenon of double refraction to the arrangement of the molecules in crystals.
=== Supplements === α-KIC has been studied as a nutritional supplement to aid in the performance of strenuous physical activity. Studies have shown that taking ɑ-KIC and its derivatives before acute physical activity led to an increase in muscle work by 10%, as well as a decrease in muscle fatigue during the early phase of the physical activity. When taken with other supplements over a two-week period, such as beta-hydroxy beta-methylbutyrate (HMB), participants reported delayed onset of muscle soreness, as well as other positive effects such as increased muscle girth. Studies have also suggested that ɑ-KIC taken alone did not have any significant positive impacts on physical performance, so it should be taken in conjunction with other ergogenic substances. ɑ-KIC is not available as a supplement on its own, but its decarboxylated form HMB is available in calcium salt capsules or powder.
The breakthrough for large molecule laser desorption ionization came in 1987 when Koichi Tanaka of Shimadzu Corp. and his co-workers used what they called the "ultra fine metal plus liquid matrix method" that combined 30 nm cobalt particles in glycerol with a 337 nm nitrogen laser for ionization. Using this laser and matrix combination, Tanaka was able to ionize biomolecules as large as the 34,472 Da protein carboxypeptidase-A. Tanaka received one-quarter of the 2002 Nobel Prize in Chemistry for demonstrating that, with the proper combination of laser wavelength and matrix, a protein can be ionized. Karas and Hillenkamp were subsequently able to ionize the 67 kDa protein albumin using a nicotinic acid matrix and a 266 nm laser. Further improvements were realized through the use of a 355 nm laser and the cinnamic acid derivatives ferulic acid, caffeic acid and sinapinic acid as the matrix. The availability of small and relatively inexpensive nitrogen lasers operating at 337 nm wavelength and the first commercial instruments introduced in the early 1990s brought MALDI to an increasing number of researchers. Today, mostly organic matrices are used for MALDI mass spectrometry.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.